EntityQ409898· pop 24· linked from 222 articles

dapagliflozin

Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

Key facts

Drug.image: Dapagliflozin skeletal.svg
Drug.image_class: skin-invert-image
Drug.width: 275
Drug.image2: Haworth projection of dapagliflozin.svg
Drug.image_class2: skin-invert-image
Drug.width2: 225
Drug.caption: Haworth projection (bottom)
Drug.imageR: Dapagliflozin-from-xtal-Mercury-3D-bs.png
Drug.image_classR: bg-transparent
Drug.widthR: 250
Drug.tradename: Farxiga, Forxiga, others
Drug.MedlinePlus: a614015
Drug.DailyMedID: Dapagliflozin
Drug.pregnancy_AU: D
Drug.routes_of_administration: By mouth
Drug.class: Sodium-glucose co-transporter 2 (SGLT2) inhibitor
Drug.ATC_prefix: A10
Drug.ATC_suffix: BK01

via Wikipedia infobox

Article

12 sections

Contents

Medical uses
Effects in nondiabetic chronic kidney disease
Adverse effects
Chemistry
Mechanism of action
Selectivity
Names
History
Society and culture
Legal status
Research
References

{{Infobox drug | image = Dapagliflozin skeletal.svg | image_class = skin-invert-image | width = 275 | alt = | image2 = Haworth projection of dapagliflozin.svg | image_class2 = skin-invert-image | width2 = 225 | alt2 = | caption = Haworth projection (bottom) | imageR = Dapagliflozin-from-xtal-Mercury-3D-bs.png | image_classR = bg-transparent | widthR = 250 | altR =